NCT04560270View on ClinicalTrials.gov

CIrculating Tumor DNA for Monitoring Response to First Line Chemotherapy in Unresectable PANcreatic Cancer

NACompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

April 25, 2016

Primary Completion Date

June 28, 2019

Study Completion Date

November 15, 2019

Conditions
Pancreatic CancerCirculating Tumor DNAKRAS Mutation-Related Tumors
Interventions
DIAGNOSTIC_TEST

Blood samples

Blood samples to determine ctDNA levels during chemotherapy

All Listed Sponsors
lead

Poitiers University Hospital

OTHER

NCT04560270 - CIrculating Tumor DNA for Monitoring Response to First Line Chemotherapy in Unresectable PANcreatic Cancer | Biotech Hunter | Biotech Hunter